IPOPI and SAFE oppose calls to reduce IG therapies for PID patients
IPOPI and the SAFE Task Force object to reducing the clinical use of immunoglobulin (IG) therapies to achieve regional sufficiency in plasma and plasma derived medicinal products (PDMPs), as it has been advocated for in recent publications.
We believe that it is essential to continue making efforts to increasing plasma collection, and therefore IG supply, for patients in need of these live-saving treatments.
All ethical debates should revolve around allowing people in need to access their life saving treatments. Not by restricting access to PDMPs or limiting the collection of plasma and production of these therapies, but by strengthening plasma collection in all world regions and the development, where appropriate, of fractionation programmes.